Alignment Healthcare Inc. (ALHC) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-01, Alignment Healthcare Inc. (NASDAQ: ALHC) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $8.06 (-1.47% 1D, market cap $1.67B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, ALHC ranks #120 in composite RQD confidence.
Within the Health Care sector (Medical Specialities), ALHC carries a Roarable C+ (67/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 13.9%. By comparison, PSNL (Personalis Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.70B) and FRNM (Freenome Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -3.4%, cap $1.38B). Among the 5-stock peer group, TRUP leads on earnings multiple (68.2x) while ALHC leads on capital efficiency (13.9% ROIC).
Per ALHC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001832466), Alignment Healthcare Inc. generated $3.95B in revenue (+46.1% YoY), -$724.0K in net income, and $113.1M in free cash flow against $1.07B in total assets and $323.2M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 2.9% FCF Margin ($113.1M FCF) & 52% Gross Margin
SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)
Put hedging (50% put share) caps near-term gamma upside (-10 pts vs max)
Even with a 67/100 (C+) score, ALHC faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($9.87) or 200D SMA ($16.81) invalidates the momentum regime and cuts Target Base ($8.39) toward Bear Floor ($6.54).
Alignment Healthcare Inc. (ALHC) slipped -1.47% to $8.06, trading at 11% of its 52-week range ($6.01 – $25.12). Solid steady margins (14% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Alignment Healthcare stock has been hit hard over the past few years, and with earnings now under a brighter spotlight, investors are asking whether the current valuation still lines up with the story they thought they o
Health insurance company Alignment Healthcare (NASDAQ:ALHC) beat Wall Street’s revenue expectations in Q3 2026, with sales up 36.7% year on year to $1.36 billion. Revenue guidance for the full year exceeded analysts’ est
Alignment Healthcare (ALHC) just released its third quarter 2026 report, pairing revenue of about US$1.36b with a net loss of US$8.05m, along with updated guidance that lifts full year sales expectations. The short-term
Alignment Healthcare (NasdaqGS:ALHC) saw its California HMO plan Star Rating downgraded by the Centers for Medicare & Medicaid Services, removing eligibility for quality bonus payments. The loss of quality bonus payments
JP Morgan analyst John Stansel maintains Alignment Healthcare (NASDAQ:ALHC) with a Overweight and lowers the price target from $10 to $8.
Revenue surged 36.7% but profitability guidance fell as medical costs climbed.
Moby summary of Alignment Healthcare, Inc.'s Q3 2026 earnings call
Barclays analyst Andrew Mok maintains Alignment Healthcare (NASDAQ:ALHC) with a Equal-Weight and lowers the price target from $10 to $9.
U.S. futures fell as Pinterest missed Q3 estimates and cut guidance; Intel, ATEC, Reddit, Roblox and others slid sharply premarket.
Keybanc analyst Matthew Gillmor downgrades Alignment Healthcare (NASDAQ:ALHC) from Overweight to Sector Weight.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +46.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ALHC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ALHC. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Alignment Healthcare Inc. (ALHC) ranks #120 by composite RQD confidence (67/100, grade C+) and #291 by equity capitalization ($1.67B). Within this direct 5-issuer industry benchmark cohort, TRUP leads on earnings valuation at 68.2x trailing P/E, while ALHC leads on capital efficiency and profitability with 13.9% ROIC and — gross margin. ALHC currently leads its immediate peer cohort in composite quantitative strength at 67/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ALHC
ACTIVE
Alignment Healthcare Inc. | C+ | 67/100 | — | — | 13.9% | -1.47% | $1.67B | Benchmark Subject |
| PSNL Personalis Inc. | D- | 36/100 | — | 22.7% | -35.0% | -0.47% | $1.70B | /psnl-vs-alhc → |
| FRNM Freenome Inc. | E | 31/100 | — | — | -3.4% | -4.32% | $1.38B | /frnm-vs-alhc → |
| TRUP Trupanion Inc. | C | 64/100 | 68.2x | 16.1% | 3.1% | +2.27% | $1.32B | /trup-vs-alhc → |
| FTRE Fortrea Holdings Inc. | D- | 35/100 | — | — | -35.0% | -10.61% | $2.20B | /ftre-vs-alhc → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Alignment Healthcare Inc. (ALHC) reported GAAP revenue of $3.95B (+46.1% vs. FY2024 revenue of $2.70B , and +119.3% cumulative change since FY2023) , GAAP net income of -$724.0K, operating cash flow of $139.9M, and free cash flow of $113.1M (+1802.0% YoY). On the balance sheet, ALHC closed FY2025 with $1.07B in total assets against $323.2M in total debt (Altman Z-Score: 4.00, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $3.95B | -$724.0K | $139.9M | $113.1M | $1.07B | $323.2M |
| FY2024 (FY) | 2024-12-31 | $2.70B | -$128.0M | $34.8M | -$6.6M | $782.1M | $321.4M |
| FY2023 (FY) | 2023-12-31 | $1.80B | -$148.0M | -$59.2M | -$59.2M | — | — |
As of 2026-11-01, Alignment Healthcare Inc. (NASDAQ: ALHC) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $8.06 (-1.47% 1D, market cap $1.67B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, ALHC ranks #120 in composite RQD confidence.
Within the Health Care sector (Medical Specialities), ALHC carries a Roarable C+ (67/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 13.9%. By comparison, PSNL (Personalis Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.70B) and FRNM (Freenome Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -3.4%, cap $1.38B). Among the 5-stock peer group, TRUP leads on earnings multiple (68.2x) while ALHC leads on capital efficiency (13.9% ROIC).
Per ALHC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001832466), Alignment Healthcare Inc. generated $3.95B in revenue (+46.1% YoY), -$724.0K in net income, and $113.1M in free cash flow against $1.07B in total assets and $323.2M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
ALHC last traded at $8.06 (-1.47% on volume of 13,586,844 shares), positioning the stock -18.34% below its 50-day simple moving average ($9.87) and -52.05% below its 200-day simple moving average ($16.81). Across its 52-week range of $6.01 to $25.12, ALHC sits at the 10.7% percentile with a 14-day RSI of 31.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($7.05 to $9.07).
Why ALHC Stock slipped -1.47% Today — RQD Quant Desk Flash. Solid steady margins (14% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.